Genenta Science (NASDAQ:GNTA) Trading Down 4.9% – Time to Sell?

Shares of Genenta Science S.p.A. (NASDAQ:GNTA) traded down 4.9% during trading on Wednesday . The company traded as low as $4.44 and last traded at $4.70. 8,527 shares changed hands during trading, a decline of 16% from the average session volume of 10,173 shares. The stock had previously closed at $4.94.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Genenta Science in a report on Wednesday, October 2nd.

Genenta Science Price Performance

The business’s fifty day moving average price is $4.80 and its 200-day moving average price is $4.08.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Genenta Science stock. AlTi Global Inc. purchased a new stake in shares of Genenta Science S.p.A. (NASDAQ:GNTA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned approximately 1.10% of Genenta Science as of its most recent SEC filing. 15.13% of the stock is currently owned by institutional investors.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.